Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study

Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina S M Yip, Zhengguang Lu, Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina S M Yip, Zhengguang Lu

Abstract

We report data from the final analysis of the Chinese subset of the GIDEON (the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study, which evaluated the safety and efficacy of sorafenib in Child-Pugh A, B and C patients with unresectable hepatocellular carcinoma (uHCC) in real-life clinical practice. Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events (AEs) and efficacy were recorded at follow-up. Of the 338 evaluable patients, 98.5% started on 800 mg/day sorafenib, regardless of their Child-Pugh status. The median treatment duration (21.1 vs. 18.8 weeks) and median overall survival (322 vs 240 days) were longer in patients with Child-Pugh A compared with the Child-Pugh B, progression-free survival were 183 vs. 208 days, respectively). AEs (all grades) were comparable in the Child-Pugh B vs A group (56.3% vs. 50.4%, respectively), moreover, the Child-Pugh B group also had comparable rates of drug-related AEs (35.4% vs. 27.2%, respectively) and serious AEs (25.0% vs. 23.0%, respectively) compared with the Child-Pugh A group. The overall dosing strategy was consistent in Chinese patients across Child-Pugh subgroups. Tolerability and safety data suggest that Child-Pugh B patients might be safely treated with sorafenib. The findings from our study showed that safety profile of sorafenib in terms of rate and type of AEs is similar to the global international GIDEON study as well as other pivotal studies.

Keywords: Child-Pugh; Chinese subset; GIDEON; sorafenib; unresectable hepatocellular carcinoma.

Conflict of interest statement

CONFLICTS OF INTEREST

The authors have provided signed confirmations to the publisher of their compliance with all applicable legal and ethical obligations in respect to declaration of conflicts of interest, funding, authorship, and contributorship, as well as compliance with ethical requirements with respect to treatment of human and animal test subjects. All the authors–Sheng-Long Ye, Xiaoping Chen, Jiamei Yang, Ping Bie, Shuijun Zhang, Fengyong Liu, Luming Liu, Jie Zhou, Kefeng Dou, Chunyi Hao, Guoliang Shao, Qiang Xia, Yajin Chen, Jijin Yang, Xiaxing Deng, Yunpeng Liu, Yunfei Yuan, Zhiren Fu, Keiko Nakajima, Christina Sm Yip, and Zhengguang LU–declared that they have no conflicts of interest to disclose.

Figures

Figure 1. Duration of treatment by Child-Pugh…
Figure 1. Duration of treatment by Child-Pugh status
Figure 2. Time to onset of adverse…
Figure 2. Time to onset of adverse events greater than grade 1 by Child-Pugh status
Figure 3. Overall survival in the Chinese…
Figure 3. Overall survival in the Chinese subset
Figure 4. Overall survival by Child-Pugh score
Figure 4. Overall survival by Child-Pugh score

References

    1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.
    1. Cancer Facts and Figures 2015 American Cancer Society. 2015 Available from: Accessed Jul 31, 2015.
    1. Liver Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012 GLOBOCAN 2012, World Health Organization Website. Available from: Accessed August 19, 2015.
    1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42:S206–S214.
    1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
    1. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21:401–416.
    1. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15:5–13.
    1. Wu Q, Qin SK. Features and treatment options of Chinese hepatocellular carcinoma. Chin Clin Oncol. 2013;2:38.
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
    1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917.
    1. Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van BP, Elder DE, Wang Y, Nathanson KL, Herlyn M. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009;28:85–94.
    1. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129–3140.
    1. Berretta M, Di BF, Dal ML, Cacopardo B, Nasti G, Facchini G, Bearz A, Spina M, Garlassi E, De R V, Fiorica F, Lleshi A, Tirelli U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs. 2013;24:212–218.
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
    1. Furuse J. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Biologics. 2008;2:779–788.
    1. Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. Hepatogastroenterology. 2014;61:954–957.
    1. Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol. 2010;22:1106–1110.
    1. Guidelines for the diagnosis and treatment of primary liver cancer (2011 edition). Ministry of Health of China 2011. Chin Clin Oncol. 2012;1:10.
    1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
    1. Yao X, Yan D, Liu D, Zeng H, Li H. Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma. Mol Clin Oncol. 2015;3:929–935.
    1. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract. 2010;64:1034–1041.
    1. Daniele B, Ratziu V, Stal PI, Serejo F, Bodoky G, Croitoru AE, et al. Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems. 2014 ASCO Annual Meeting 2015; Available from: . Accessed Aug 1, 2015.
    1. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladron de GL, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012;66:675–683.
    1. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014;68:609–617.
    1. Marrero JA, Lencioni R, Ye SL, Kudo M, Bronowicki JP, Chen XP, et al. Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction. 2013 ASCO Annual Meeting 2015; Available from: . Accessed Aug 1, 2015.
    1. European Medical Agency; 2007. EUDRALEX : The rules governing medicinal products in the European Union. Available from: . Accessed Jun 1, 2014.
    1. Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther. 2011;34:1193–1201.
    1. Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Camma C, Colombo M. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011;54:2055–2063.
    1. Kim JE, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol. 2011;68:1285–1290.
    1. Pinter M, Sieghart W, Graziadei I, Vogel W, Maieron A, Konigsberg R, Weissmann A, Kornek G, Plank C, Peck-Radosavljevic M. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist. 2009;14:70–76.
    1. Pressiani T, Boni C, Rimassa L, Labianca R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C, Mucciarini C, Latini L, Carnaghi C, Banzi M, et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol. 2013;24:406–411.
    1. Worns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Duber C, Otto G, Galle PR. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009;43:489–495.
    1. Daniele B, Croitoru A, Papandreou C, Bronowicki JP, Mathurin P, Serejo F, Stål P, Turnes J, Ratziu V, Bodoky G. Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncol. 2015;11:2553–2562.
    1. Turnes J, Díaz R, Hernandez-Guerra M, Gómez M, Castells L, Bustamante J, Espinosa MD, Fernández-Castroagudín J, Serrano T, Rendón P, Andrade R, Salgado M, Arenas J, et al. Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain. Gastroenterol Hepatol. 2015;38:263–273.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere